BGPartner berät Araris Biotech AG bei Finanzierungsrunde von CHF 24 Mio.

BGPartner hat die Araris Biotech AG bei einer Finanzierungsrunde von CHF 24 Millionen beraten, an der die beiden Co-Lead-Investoren 4BIO Capital und Pureos Bioventures beteiligt waren.

Araris Biotech AG, ein Unternehmen, das Pionierarbeit auf dem Gebiet der Antikörper-Wirkstoff-Konjugat (ADC)-Linker-Technologie leistet, beabsichtigt, den Erlös für die Weiterentwicklung der führenden ADCs in der präklinischen und klinischen Entwicklung zu verwenden.

BGPartner unterstützte Araris Biotech Ltd. bei den Verhandlungen und beriet in allen schweizerischen Rechtsfragen im Zusammenhang mit dieser Finanzierungsrunde.

Team von BGPartner

Das Team von BGPartner wurde von Oliver Gnehm (Partner) geleitet und bestand ferner aus Thomas Gysin (Senior Associate).

Information von Araris Biotech AG über die Transaktion

Die Araris Biotech AG informierte wie folgt über die Transaktion:

Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine. Damir Illich, Ph.D. from Wille AG and Sophie Allauzen, Ph.D. from the Institute for Follicular Lymphoma Innovation will also be joining the Araris team as board observers.

Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical development.

“We’re thrilled to have support from this group of investors who recognize the potential of our linker technology in this exciting and growing ADC field and look forward to using these proceeds to support our efforts in advancing our ADC candidates toward the clinic,” said Philipp Spycher, Ph.D., chief executive officer at Araris Biotech.

“Our linker technology has enabled us to create ADCs in a single conjugation step. The resulting ADCs have shown a significantly improved therapeutic index and favorable biophysical properties in preclinical studies to date, and an ability to address the limitations of current ADCs on the market. This fundraising will allow us to move closer to our goal of bringing these therapies to patients in need of better treatment options.” Dmitry Kuzmin, Ph.D., managing partner at 4BIO Capital, added, “Araris continues to make waves in the industry with its pioneering linker technology, enabling fast and precise production of ADCs. Having invested in Araris’ seed round, we are now delighted to co-lead the latest round to ensure that Araris can unlock the potential of its differentiated technology and bring highly effective therapies to patients across the world.” Dominik Escher, Ph.D., founding partner at Pureos Bioventures stated, “We are pleased to continue our support for Araris in this financing round as the company advances the next generation of antibody-drug conjugates with the potential to help cancer patients in the future.”


Kommentare (0)

Wir verwenden Cookies, um unsere Website und Ihr Navigationserlebnis zu verbessern. Wenn Sie Ihren Besuch auf der Website fortsetzen, stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zum Datenschutz finden Sie hier.